Jupiter Neurosciences, Inc. closed a registered direct offering on August 24, 2026, issuing and selling 307,692 shares of common stock at $6.50 per share to raise approximately $2.0 million in aggregate gross proceeds. The company states that these proceeds bring its stockholders' equity above the $2.5 million minimum requirement for continued listing on The Nasdaq Capital Market, though it awaits formal confirmation from Nasdaq and warns of potential delisting if compliance is not evidenced by the next periodic report. Jupiter Neurosciences, Inc. operates in the biotechnology industry, focusing on the development of therapies for neurological disorders.
